Synthetic cannabinoids (SCs) are a chemically diverse group of new psychoactive
substances (NPSs) that target the endocannabinoid system, triggering a plethora of actions …

Traumatic brain injury is common, and often results in debilitating consequences. Even mild
traumatic brain injury leaves approximately 20% of patients with symptoms that persist for …

With new synthetic cannabinoids (SCs) appearing on the European drug market every year,
early warning systems are key to detect, monitor, and respond to threats posed by them. The …

Synthetic cannabinoids (SCs) make up a class of novel psychoactive substances (NPS),
used predominantly in prisons and homeless communities in the UK SCs can have severe …

The emergence of synthetic cannabinoid receptor agonists (SCRAs) as illicit psychoactive
substances has posed considerable public health risks, including fatalities. Many SCRAs …

Synthetic cannabinoid receptor agonists (SCRAs) are a diverse class of new psychoactive
substances (NPS). They commonly comprise N-alkylated indole, indazole, or 7-azaindole …

A new concept of paper-based device has been developed combining the advantages of
cellulose supports and the rich surface chemistry of metal-organic frameworks (MOFs). The …

The rapid structural evolution and emergence of novel synthetic cannabinoid receptor
agonists (SCRAs) in the recreational market remains a key public health concern. Despite …

Class AG protein‐coupled receptors (GPCRs) continue to garner interest for their essential
roles in cell signalling and their importance as drug targets. Although numerous drugs in the …

The cannabinoid CB 1 receptor (CB 1) is a G protein-coupled receptor (GPCR) with
widespread expression in the central nervous system. This canonically G⍺ i/o-coupled …